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ABBREVIATIONS
ºC         :     Degree Centigrade
Abs       :     Absorbance
µl          :          Micro litre
µg/ml    :          micro gram  per millilitre
λmax     :         Lambda maximum
mg         :         Milligrams
g             :        Grams
SD         :         Standard deviation
Kg/cm2   :          kilogram per centimetre square
min        :         Minute
ml          :         Milli litre
N            :         Normal
Nm         :         Nanometre
RPM      :         rotation per minute
Hr          :         Hour
Sec         :         Second
Vd         :          Volume of distribution
Cm        :          Centimetre
nm         :         Nanometre
Cps        :         Centi poise
HPMC    :         Hydroxy Propyl Methyl cellulose
PVA       :           Poly Vinyl Alcohol
      %w/w          :           Percentage weight by weight
     Q.S                :           quantity sufficient
    ISMN             :          Isosorbide mononitrate
      FTIR            :          Fourier transfer infrared spectroscopy
     Kg/mm2             :          Kilogram per millimetre square
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1. INTRODUCTION
The oral route of administration continues to be most preferred route due
to  various  advantages   including  ease  of  administration,  avoidance  of
pain, versatility(1)  and are administered in the form of  both solid dosage
forms(powders,  pills,  spansules,  moulded  tablets)  and  liquid  dosage
forms (elixirs, syrups, emulsions, mixtures). A pill can be designed for
swallowing or chewing to deliver  a  precise dose of  medication to  the
patients. Under moderate pressure, the pills including tablets and capsules
are able to retain their shapes. Major disadvantage of this route is the
difficulty in swallowing or chewing solid dosage forms particularly in
pediatric  and geriatric  patients (2).  Due to fear  of  throat choking many
pediatric  and  geriatric  patients  are  unwilling  to  take  these  solid
preparations(4). In order to overcome the difficulties associated with this
system of administration, several fast  dissolving drug delivery systems
have been developed. By using variety of technologies, including direct
compression,  wet  granulation  and  freeze  drying  Fast  dissolving  drug
delivery systems can be manufactured. In order to dissolve the dosage
form rapidly  in  the  mouth,  some  make  use  of  different  disintegrating
mechanisms, such as high level of disintegrating or effervescent agents.
Because of its easy administration and better compliance, recently fast
dissolving  drug  delivery  system  have  started  gaining  popularity  and
acceptance as new drug delivery systems. Without the need of water or
chew to aid in swallowing, these fast dissolving drug delivery systems
can  be  dissolve  or  disintegrate  in  the  patient’s  mouth  within  a  few
seconds  or  minutes(3).  Oral  film  drug  delivery  is  a  better  alternative
against  oral  solid tablets because of its fear of taking and the risk of
choking  for  certain  patient  populations  even  it  has  short
disintegration/dissolution  times  and  also  the  oral  availability  of  many
drugs are very poor because of the pH  stomach, the presence of enzymes,
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extensive first-pass metabolism these can also be solved by making oral
films.  These drugs have been administered as parenteral  drug delivery
systems,  but  because  of  poor  patient  compliance  the  pharmaceutical
industry  look  for  alternative  routes  of  drug  delivery  like  film  drug
delivery. Intraoral fast-dissolving drug delivery system is placed on the
top or the floor of the tongue. It is retained at the site of application and
rapidly releases  the  active  agent  for  local  and/or  systemic  absorption.
They also impart unique product differentiation, thus enabling use as line
extensions for  existing  commercial  products.  This  novel  drug delivery
system can also have an advantage for meeting the current needs of the
industry  are  improved  solubility/stability,  biological  half  life  and
bioavailability enhancement of drugs.(5),(6)
1.1 Overview of oral cavity: (7),(8)
1.1.1 Structural Features of Oral Mucosa
The  oral  mucosa  is  composed  of  an  outermost layer  of  stratified
squamous epithelium  Below this lies a basement membrane, a lamina
propria  followed  by  the  submucosa  as  the  innermost  layer.  The
epithelium is similar to stratified squamous epithelia found in the rest of
the body in that  it  has a mitotically active basal  cell  layer,  advancing
through a number of differentiating intermediate layers to the superficial
layers,  where  cells  are  shed  from the  surface  of  the  epithelium .The
turnover time for the buccal epithelium has been estimated at 5-6 days
and this is probably representative of the oral mucosa as a whole. The
oral mucosal thickness varies depending on the site: the buccal mucosa
measures at 500-800 µm, while the mucosal thickness of the hard and soft
palates,  the  floor  of  the  mouth,  the  ventral  tongue  and  the  gingivae
measure at about 100-200 µm. The composition of the epithelium also
varies  depending  on  the  site  in  the  oral  cavity.  The  mucosae  of  the
gingivae and hard palate are keratinized similar to the epidermis which
containe  ceramides  and acylceramides (neutral  lipids)which have been
associated with the barrier function. The mucosa of the soft palate, the
sublingual and the buccal regions, however, are not keratinized which are
relatively  impermeable  to  water  and  only  have  small  amounts  of
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ceramide. They also contain small  amounts of neutral  but polar lipids,
mainly cholesterol  sulfate  and glucosyl  ceramides.  The nonkeratinized
epithelia have been found to be considerably more permeable to water
than keratinized epithelia.
                          Figure No.1   Structure of Oral cavity
1.2  Classification Of Fast Dissolve Technology:
Fast-dissolve technologies can be divided in to three broad groups:
1.Lyophilized systems, 
2.Compressed tablet-based systems, 
3 Thin film strips. 
1.2.1 The lyophilized systems:
This system is the most successful among them in terms of sales value,
sales volume and number of worldwide product approvals. Through the
use of a mould or blister pack, suspension or solution of drug with other
structural  excipients will  convert  into tablet-shaped units.  The units or
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tablets are then frozen and lyophilized in the pack or mould. The resulting
units  having  high  porosity  are  responsible  for  rapid  water  or  saliva
penetration and very rapid disintegration.  Dose-handling capability for
these  systems  differs  depending  on whether  the  active  ingredients  are
soluble or insoluble drugs, with the dose capability being slightly lower
for the former than for some tablet based systems. The units are capable
of incorporating a range of taste-masked materials and have more rapid
disintegration than tablet-based systems.
1.2.2 Compressed tablet-based systems:
This  system  is  produced  using  standard  tablet  technology  by  direct
compression of excipients. The tablet technologies have different levels
of hardness and friability depending on the method of manufacture..The
speed of disintegration for fast-dissolve tablets compared with a standard
tablet  is  achieved  by  formulating  using  water  soluble  excipients,  or
superdisintegrant or effervescent components, to allow rapid penetration
of water into the core of the tablet. The one exception to this approach for
tablets is Biovail.s Fuisz technology. It uses the proprietary Shear form
system  to  produce  drug-loaded  candy  floss,  which  is  then  used  for
tableting  with  other  excipients.  These  systems  can  theoretically
accommodate  relatively  high  doses  of  drug  material,  including  taste-
masked  coated  particles.  The  potential  disadvantage  is  that  they  take
longer to disintegrate than the thin-film or lyophilized dosage forms. The
loose compression tablet approach has increasingly been used by some
technology  houses,  branded  companies  and  generic  pharmaceutical
companies, for in-house development of line extension and generic fast-
dissolve dosage forms.(9)
1.2.3 Oral Thin Films (OTF):
Oral films, also called oral wafers in the related literature, are a group of
flat films which are administered into the oral cavity. Although oral film
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systems, the third class, have been in existence for a number of years,
they  have  recently  become  the  new  area  of  interest  in  fast-dissolve
pharmaceutical drug delivery. Dissolvable oral thin films (OTFs) or oral
strip (OS) evolved over the past few years from the confection and oral
care markets in the form of breath strips and became a novel and widely
accepted form by consumers for delivering vitamins and personal care
products.  Companies  with  experience  in  the  formulation  of  polymer
coatings  containing  active  pharmaceutical  ingredients  (APIs)  for
transdermal drug delivery capitalized on the opportunity to transition this
technology  to  OTF formats.  Today,  OTFs  are  a  proven  and  accepted
technology for the systemic delivery of APIs for over-the-counter (OTC)
medications  and  are  in  the  early-  to  middevelopment  stages  for
prescription  drugs(10).  This  is  largely  as  a  result  of  the  success  of  the
consumer breath freshener products such as Listerine PocketPaks in the
US consumer market. Such systems use a variety of hydrophilic polymers
to  produce  a  50-200  mm  film  of  material.  This  film  can  reportedly
incorporate soluble, insoluble or taste-masked drug substances. The film
is manufactured as a large sheet and then cut into individual dosage units
for packaging in a range of pharmaceutically acceptable formats(9).
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Property  /  Sub
Type
Flash release water Mucoadhesive  melt
away wafer
Mucoadhesive  sustained
release wafer
Area (cm2) 2-8 2-7 2-4
Thickness(µm) 20-70 50-500 50-250
Structure Film: single layer Single or Multilayer Multilayer
Excipients
Soluble,highly
hydrophilic polymers
Soluble,hydrophilic
polymers
Low,non-soluble
polymers
Drug phase
Solid solution
Solid solution or
suspended drug
particles
Suspended  and/or  solid
solution
Application
Tongue(upper plate) Gingival  or  Buccal
region
Gingival or buccal Region
Gingival, (other region in
the oral cavity
Dissolution
Maximum 60 seconds Disintegration  in  a
few  minutes,  forming
gel
Maximum 8-10hours
Site of action
Systemic or local Systemic or local Systemic or local
           Table No.1 , Types of wafers and their properties
1.2.3.1 Classification of Oral Film:
There are three different subtypes
(1)Flash release, 
(2)Mucoadhesive melt-away wafer, 
(3)Mucoadhesive sustained-release wafers. 
1.2.3.2 Advantages of Oral Thin Film:
This  dosage  form  enjoys  some  distinct  advantages  over  other  oral
formulations such as-
• Availability of larger surface area that leads to rapid disintegrating
and dissolution in the oral cavity. 
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• The disadvantage of  most  ODT is that  they are fragile  and brittle
which warrants special  package for  protection during storage and
transportation. Since the films are flexible they are not as fragile as
most of the ODTs. Hence, there is ease of transportation and during
consumer handling and storage. 
• As  compared  to  drops  or  syrup  formulations,  precision  in  the
administered dose is ensured from each of the strips. 
• Pharmaceutical  companies  and  consumers  alike  have  embraced
OTFs  as  a  practical  and  accepted  alternative  to  traditional  OTC
medicine forms such as liquids,  tablets, and capsules.  OTFs offer
fast, accurate dosing in a safe, efficacious format that is convenient
and portable, without the need for water or measuring devices(11)  
• The oral or buccal mucosa being highly vascularized, drugs can be
absorbed  directly  and  can  enter  the  systemic  circulation  without
undergoing  first-pass  hepatic  metabolism.  This  advantage  can  be
exploited in preparing products with improved oral bioavailability of
molecules that undergo first pass effect(12). 
• Since the first pass effect can be avoided, there can be reduction in
the dose which can lead to reduction in side effects associated with
the molecule. 
• Patients suffering from dysphagia, repeated emesis, motion sickness,
and mental disorders prefer this dosage form as they are unable to
swallow large quantity of water. 
• OTFs are typically the size of a postage stamp and disintegrate on a
patients tongue in a matter of seconds for the rapid release of one or
more  APIs.  The  formulation  of  dissolvable  films  is  customarily
facilitated  through  aqueous  polymer  matrices  that  span  a  wide
molecular  weight  (MW)  range,  thereby  providing  flexibility  to
achieve certain physical properties. 
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 1.2.3.3 Disadvantage of Oral Thin films:
The  disadvantage  of  Oral  thin  film  is  that  high  dose  cannot  be
incorporated into the strip. However, research has proven that the
concentration level of active can be improved up to 50% per dose
weight(11). There remain a number of technical limitations with the
use  of  film  strips.  The  volume  of  the  dosage  unit  is  clearly
proportional to the size of the dose, which means these extremely
thin  dosage  forms  are  best  suited  to  lower-dose  products.  As  an
example of this, Labtec claim that the Rapid Film technology can
accommodate dose of up to 30 mg. This clearly limits the range of
compatible drug products. The other technical challenge with these
dosage forms is achieving Dose Uniformity(9).
  1.2.3.4  Application of Oral Films in Drug Delivery:
        Oral mucosal delivery via Buccal, sublingual, and mucosal route by
use  of  OTFs  could   become  a  preferential  delivery  method  for
therapies in which rapid absorption is desired, including those used
to  manage  pain,  allergies,  sleep  difficulties,  and  central  nervous
system disorders.
     1.2.3.5  Advantages of oral fast dissolving films.
Oral mucosal delivery via Buccal, sublingual, and mucosal route by
use  of  OTFs  could  become  a  preferential  delivery  method  for
therapies in which rapid absorption is desired, including those used
to  manage  pain,  allergies,  sleep  difficulties,  and  central  nervous
system disorders. 
•Topical applications: The use of dissolvable films may be feasible in
the  delivery  of  active  agents  such  as  analgesics  or  antimicrobial
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ingredients for wound care and other applications.
 •Gastro  retentive  dosage  systems:  Dissolvable  films  are  being
considered in dosage forms for which water-soluble and poorly soluble
molecules  of  various  molecular  weights  are  contained  in  a  film
format(13) Dissolution  of  the  films  could  be  triggered  by  the  pH or
enzyme secretions of the gastrointestinal tract, and could potentially be
used to treat gastrointestinal disorders.
• Diagnostic devices:  Dissolvable films may be loaded with sensitive
reagents to allow controlled release when exposed to a biological fluid
or to create isolation barriers for separating multiple reagents to enable
a timed reaction within a diagnostic device(14)
1.3 Oral films Formulation consideration
Oral dissolving film is a thin film with an area of 1-20 cm2 (depend on
dose and drug loading) containing drug.  Drugs can be loaded up to a
single  dose  of  30mg.  The  important  factors  affecting  mechanical
properties  of  the  films  are  the  formulation  considerations  (plasticizers
etc). 
A typical composition contains the following components:
Drug                                                       5% to30%w/w
 Water soluble polymer                           45%w/w
 Plasticizers                                             0-20%w/w
 Surfactants                                             q.s
 Sweetening agent                                   3 to 6 %w/w
 Saliva stimulating agent                         2 to 6%w/w
     Fillers, colors, flavors etc. q.s(15)
    1.3.1 Film Forming Polymers
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For the preparation of fast  dissolving films,  a variety of polymers are
available. In order to obtain the desired strip properties, the polymers can
be used alone or  in combination.  To avoid damage while  handling  or
during transportation, the film obtained should be tough. Type of polymer
and  the  amount  in  the  formulation  are  the  factors  which  help  in  the
robustness of the strip. On the other hand, fast dissolving strip dosage
form should have the property to disintegrate in seconds when placed in
mouth a deliver the drug to the oral  cavity   instantaneously.  Lists of
polymers which are used in oral strip are given in table 
                                         
Table No.2 ,List of polymers used in oral film formulation
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Pullulan Sodium carboxy methyl cellulose
Gelatin Hydroxyl ethyl cellulose
Hydroxyl propyl methyl
cellulose (hypromellose)
xanthan gum
Polyvinyl Pyrrolidone
(PVP)
Iocust bean gum
Modified starches Guar gum
Polyvinyl alcohol Carrageenan
Polpolyethylene oxide Low viscocity grade HPC
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 At  least  45%w/w  of  polymer  should  generally  be
present  based  on  the  total  weight  of  dry,  because  the  strip
forming polymer is the most essential and major component of
the fast dissolving film. For the preparation of fast dissolving
film, most commonly used polymers are pullulan, gelatin and
hypromellose(16)
1.3.2 Plasticizers
The selection of plasticizer will depend upon its compatibility
with the polymer and also the type of solvent employed in the
casting of strip. It  helps to improve the flexibility of the strip
and reduces the brittleness of the strip. Plasticizer significantly
improves  the  strip  properties  by  reducing  the  glass  transition
temperature of the polymer in the range of  40–60 ºC for non
aqueous solvent system and below 75 ºC for aqueous systems.
Typically  the  plasticizers  are  used  in  the  concentration  of  0–
20%w/w of dry polymer weight. (16, 17).
1.3.3 Active pharmaceutical ingredient
The Oral thin film technology has the potential for delivery of variety of
APIs.  A number  of  molecules  can  be  incorporated  into  this  delivery
system.  They  may  include  cough/cold  remedies  (antitussives,
expectorants),  antianxiety  drugs,  cardiovascular  agents,  sore  throat,
erectile dysfunction drugs, antihistamines, antiasthmatics, gastrointestinal
disorders,  nausea,  pain and CNS (e.g.  anti-Parkinson’s  disease).  Other
applications comprise caffeine strips, snoring aid, multivitamins, sleeping
aid etc. However since the size of the dosage form has limitation, high
dose molecules  are  difficult  to  be incorporated in  Oral  thin films.It  is
always useful to have micronized API which will improve the texture of
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the film and also for better dissolution and uniformity .Many APIs, which
are potential candidates for OTF technology, have bitter taste. This makes
the  formulation  unpalatable  especially  for  pediatric  preparations.  Thus
before incorporating the API in the OTF, the taste needs to be masked.
Various  methods  can  be  used  to  improve  the  palatability  of  the
formulation.  Certain  pathologies  require  instantaneous  release  of  the
medicament  for  prompt  relief.  For instance,  in  the case of  migraine a
rapid clinical effect is desired by the individual. Regiospecific delivery of
the medicament  would be required in the cases  of  sore throat,  cough,
allergy and other local oral manifestations. (15,16,18).
1.3.4 Surfactants: 
           Surfactants can act as solubilizing or wetting or dispersing agent.
In formulation, the film is getting dissolved within seconds and release
active agent quickly. Some of the commonly used surfactants are sodium
lauryl sulfate, benzalkonium chloride, tweens, polyethylene glycol, etc. is
Polaxamer 407 is one of the most important surfactant that is  used as
solubilizing, wetting and dispersing agent(15)
1.3.5 Sweetening Agents 
1.3.5.1 Natural Sweeteners:
           Sweeteners have become the important component for those
nutraceuticals  as  well  as  pharmaceutical  products.  Sweetners  will
dissolve  in  the  oral  cavity.  The  sources  of  sweetener  are  sucrose,
dextrose,  fructose,  glucose,  liquid  glucose  and  isomaltose.  Fructose  is
used widely as sweetner because it is sweeter than sorbitol and mannitol.
They  additionally  provide  Because  of  good  mouth-feel  and  cooling
sensation. Polyhydric alcohols such as sorbitol, mannitol and isomalt can
be used in combination. Main advantages of Polyhydric alcohols are less
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carcinogenic  and  do  not  have  after  taste  which  is  a  vital  aspect  in
formulating oral preparations.
1.3.5.2 Artificial Sweeteners: 
           The artificial sweeteners have gained more popularity in food and
pharmaceutical preparations. The artificial sweeteners can be classified in
I generation and II generation sweeteners which are Acesulfame-K and
sucralose  have  more  than  200 and 600  time  sweetness.  Neotame and
alitame  have  more  than  2000  and  8000  time  sweetening  power  as
compared to sucrose. Rebiana which is a herbal sweetener, derived from
plant Stevia rebaudiana (South American plant) has more than 200 - 300
time sweetness (15, 18)
1.3.6 Saliva Stimulating Agent: 
               For the faster  disintegration of  the fast  dissoving film
formulations, more saliva production is needed. So the formulations may
contain  acids  which  are  used  in  the  preparation  of  food  as  salivary
stimulants. Examples of salivary stimulants are Citric acid, malic acid,
lactic acid, ascorbic acid and tartaric acid. In this Citric acid being the
most preferred amongst them(15).
1.3.7 Flavor:
               Any flavor  (US-FDA approved)  can  be  added in  the
formulation.  For  example,  intense  mints,  sour  fruit  flavors  or  sweet
confectionery flavors15. The amount of flavor needed to mask the taste
depends on the flavor type and its strength.
1.3.8 Coloring Agents:
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              Coloring agents are used mainly to  impart  a distinctive
appearance to a pharmaceutical dosage form.  Pigments such as titanium
dioxide or a full range of colors are available, including FD and C colors,
EU Colors, Natural Colors like curcumin, chlorophylls, carotenoids and
custom Pantone-matched color.(15)
1.4 Manufacturing Methods:
One or combination of the following process can be used to manufacture
the mouth dissolving films (19)
i)Solvent casting 
ii)Semisolid casting 
iii)Hot melt extrusion 
iv)Solid dispersion extrusion 
v)Rolling 
1.4.1 Solvent casting method:
The Oral fast dissolving film is preferably formulated using the solvent-
casting method. In solvent casting method water  soluble polymers are
dissolved in water and the drug along with other Excipients is dissolved
in  suitable  solvent  then  both  the  solutions  are  mixed  and  stirred  and
finally casted in to the Petri plate and dried. solution. The API and other
agents are dissolved in smaller amounts of the solution, and combined
with the bulk. This mixture is then added to the aqueous viscous solution.
The entrapped air is removed by vacuum. The resulting solution is cast as
a film and allowed to dry, which is then cut into pieces of the desired
size.
Water-soluble  hydrocolloids  used  to  prepare  RDFs  include:  hydroxyl
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propyl  methyl  cellulose  (HPMC),  hydroxyl  propyl  cellulose  (HPC),
pullulan,  sodium  alginate,  pectin,  carboxy  methyl  cellulose  (CMC),
polyvinyl alcohol (PVA). The selection of solvent essentially depends on
the API to be incorporated into the strip. The physicochemical properties
of the API like heat sensitivity, shear sensitivity, the polymorphic form of
the API employed, compatibility of the API with solvent and other strip
excipients are to be critically studied. The significant elements in this are
liquid rheology, desired mass to be cast and content or dosage uniformity.
Solvents used for the preparation of solution or suspension should ideally
be selected from ICH Class 3 solvent list.
                                                     
                             Figure No.2,    Solvent casting system
Advantages
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· Great uniformity of thickness and great clarity than extrusion 
· Film have fine gloss and freedom from defects such as die lines 
· Film have more flexibility and better physical properties 
Disadvantages 
· The polymer must be soluble in a volatile solvent or water. 
· A stable  solution  with  a  reasonable  minimum  solid  content  and
viscosity should be formed. 
Formation of a homogeneous film and release from the casting support
must be possible. (15)
1.4.2 Semisolid casting:
In  semisolid  casting  method  firstly  a  solution  of  water  soluble  film
forming polymer is prepared. The resulting solution is added to a solution
of  acid  insoluble  polymer  (e.g.  cellulose  acetate  phthalate,  cellulose
acetate  butyrate),  which  was  prepared  in  ammonium  or  sodium
hydroxide. Then appropriate amount of plasticizer is added so that a gel
mass is obtained. Finally the gel mass is casted in to the films or ribbons
using heat controlled drums. The thickness of the film is about 0.015-0.05
inches. The ratio of the acid insoluble polymer to film forming polymer
should be 1:4.(20)    
1.4.3 Hot melt extrusion:
 
In  present  method  the  mass  is  prepared  first  under  the  control  of
temperature and steering speed. Afterwards, the film is coated and dried
in a drying tunnel, once again the temperature, air circulation and line
speed are controlled. Then follows a slitting and in the last step the films
are punched and sealed. In hot melt extrusion method firstly the drug is
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mixed with carriers in solid form. Then the extruder having heaters melts
the mixture. Finally the melt is shaped in to films by the dies. (16,21) 
Advantages:
Without use of any solvent or water
Fewer processing steps
Compressibility properties of the API may not be of importance.
Better alternative for poorly soluble drugs.
More uniform dispersion because of intense mixing and agitation.
Less energy compared with high shear methods.
Disadvantages:
Thermal degradation due to use of high temperature
Flow properties of the polymer are essential to processing
Limited number of available polymers
All excipients must be devoid of water or any other volatile solvent (16).
1.4.4  Solid dispersion extrusion:
In this method immiscible components are extrude with drug and then
solid dispersions are prepared. Finally the solid dispersions are shaped in
to films by means of dies (16, 20).
1.4.5 Rolling Method:
In rolling method a solution or suspension containing drug is rolled on a
carrier. The solvent is mainly water and mixture of water and alcohol.
The film is dried on the rollers and cutter in to desired shapes and sizes.
(11) Other ingredients including active agents dissolved in small portion of
aqueous solvent using high shear processor Water soluble hydrocolloids
dissolved in water to form homogenous viscous solution. (20)
1.5 TECHNOLOGIES
1.5.1 SOLULEAVES™   
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This  is  applied  to  flavour-release  products  such  as  mouth  fresheners,
confectionery  andvitamin  products.  SOLULEAVES technology can  be
used  to  deliver  active  ingredients  to  oral  cavity  efficiently  and  in  a
pleasant  and  easily  portable  form..  SOLULEAVES™  films  can  be
designed to dissolve rapidly on contact with saliva, quickly releasing the
active  ingredients  and  flavours.  This  quality  makes  edible  films  an
excellent  delivery method for  a  large  range of  products  requiring  fast
release  in  the  mouth.  For  pharmaceutical  uses  this  method  of
administration is especially useful for pediatrics or elderly patients who
may  have  difficulty  swallowing  traditional  tablets  or  capsules.The
delivery system can be used for the cough/cold, gastrointestinal and pain
therapeutic  areas  as  well  as  delivering  nutritional  products.
SOLULEAVES™  films  can  also  be  designed  to  adhere  to  mucous
membranes and to release the active ingredient slowly over 15 minutes.
1.5. 2 WAFERTAB™ 
It  is  a  patented delivery system that uses  a unique process to  prepare
drug-loaded  thin  films  which  can  be  used  in  topical  or  oral
application.Active ingredients are incorporated into the film after casting
is a drug delivery system that incorporates pharmaceutical actives into an
ingestible filmstrip. The system provides rapid dissolution and release of
actives when the strip comes into contact with saliva in the mouth. The
WAFERTAB™ filmstrip can be flavoured for additionally improved taste
masking. The active ingredient is precisely dosed and integrated into the
body of a pre-manufactured XGEL™ film, thus preventing exposure to
unnecessary  heat  and  moisture  and  potentially  enhancing  product
stability. The WAFERTAB™ system lends itself to many possibilities for
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innovative product design, enabling multiple films with different actives
to be bonded together. WAFERTAB™ can be prepared in a variety of
shapes and sizes and is an ideal method for delivery of medicines, which
require fast release, or for use by patients who have difficulty swallowing.
1.5.3 FOAMBURST™
It is a special variant of the SOLULEAVES™ technology where an inert
gas is passed into the film during production. This results in a film with a
honeycombed structure,  which dissolves rapidly giving a novel  mouth
sensation.  FOAMBURST™  has  attracted  interest  from  food  and
confectionary  manufacturers  as  a  means  of  carrying  and  releasing
flavours. 
1.5.4  XGEL™
 This  film is at the heart of Meldex International's intellectual property,
used  in all  its  film  systems  and  its  ingestible  dosage  delivery
technologies.  XGEL™  film  provides  unique  product  benefits  for
healthcare  and  pharmaceutical  products:  it  is  nonanimal-  derived,
approved on religious grounds and is suitable for vegetarians; the film is
GMO free and continuous production processing provides an economic
and  competitive  manufacturing  platform.  XGEL™  film  can  be  taste
masked, coloured, layered, and capable of being enteric properties whilst
also having the ability to incorporate active pharmaceutical ingredients.
The XGEL™ film systems can be made to encapsulate any oral dosage
form, and can be soluble in either cold or hot water. XGEL™ film is
comprised  of  a  range of  different  water-soluble  polymers,  specifically
optimized for  the  intended use.  All  of  the XGEL ingredients  are well
known and generally regarded as safe (GRAS). XGel film Technology
developed by BioProgress is causing a revolution in the product offerings
and manufacturing methods now available to the pharmaceutical industry.
(16)
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2  Literature Review
2.1 Literature Review  
Aditya Dinge et al., (2008)  Triclosan containing fast dissolving films are developed for
local delivery to oral cavity. For the preparation of fast dissolving films Different types of
film  forming  agents,  film  modifiers  and  polyhydric  alcohols  were  evaluated  for
optimizing  the  composition  .  The  potential  of  poloxamer  407  and  hydroxypropyl-β-
cyclodextrin to improve solubility of Triclosan was investigated.  Fast dissolving films
containing hydroxypropyl  methylcellulose,  xanthan gum, and xylitol were formulated.
Use  of  poloxamer  407  and  hydroxypropyl-β-  cyclodextrin  resulted  in  significant
improvement in the solubility of Triclosan. Fast  dissolving films containing Triclosan
hydroxypropyl-β- cyclodextrin complex and Triclosan-Poloxamer 407 were formulated
and were evaluated for the in vitro dissolution profile and in vitro microbiological assay.
Films containing Triclosan-Poloxamer 407 shows better in vitro dissolution profile and in
vitro antimicrobial activity as compared to the films containing Triclosan hydroxypropyl-
β- cyclodextrin complex. (34)
Mohammed  Gulzar  Ahmed  et  al.,(2009) This  study  was  designed  to  develop  and
evaluate chitosan films containing ciprofloxacin and diclofenac sodium for the topical
treatment  of  periodontitis.  Chitosan  films  containing  ciprofloxacin  alone  and  in
combination with diclofenac sodium were prepared by solvent casting method. Some of
the  drug-loaded  films  were  crosslinked  with  2%gluteraldehyde  for  2  and  4  h,
respectively.  The  films  were  then  evaluated  for  their  physicochemical  properties
including  weight  variation,  thickness,  tensile  strength,  in  vitro  release,  stability  and
antibacterial  activity..  The  study  suggests  that  cross  linked  chitosan  film  containing
ciprofloxacin and diclofenac is a potential drug delivery device for the topical treatment
of periodontitis (35).
 Yoshinori Itoh et  al.,  (2009) Formulated fast  dissolving oral  thin film that  contains
dexamethasone  and  microcrystalline  cellulose,  polyethylene  glycol,
hydroxypropylmethyl cellulose, polysorbate 80 , low-substituted hydroxypropyl cellulose
etc. used as base materials.. This preparation showed excellent uniformity and stability, at
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temperature at 40ºC and 75% in humidity for up to 24 weeks. The film was disintegrated
within 15 s after immersion into distilled water. The Invitro dissolution test showed that
approximately 90% of dexamethasone was dissolved within 5 min.. The fast dissolving
oral  thin  film  containing  dexamethasone  is  likely  to  become  one  of  choices  of
dexamethasone preparations for antiemesis during cancer chemotherapy (36).
Sandeep  Saini  et  al.,  (2009) development  and  evaluation  of  Fast  dissolving  film of
levocetrizine dihydrochloride were prepared by solvent casting method . Maltodextrin &
Hydroxy propyl  methyl  cellulose  as  the  main  film  forming  polymers.To  reduce  the
disintegration time,concentration of maltodextrin & were optimized be using Hydroxy
propyl methyl cellulose . Disintegration time, drug release pattern, mouth dissolving time
and content uniformity were also evaluated. Compatibility between drug and recipients
were  studied  by means  of  Differiential  scanning  colorimetry analysis.  Batch  F1  was
found to be the optimized batch as its disintegration was completed within the minimum
time as compared to all other batches. The formulation (F1) was also showing sufficient
drug release after 5 min. All the 6 formulation was showing approximately 90% drug
release after 5min (37).
Francesco Cilurzo et al., (2010) develop a fast-dissolving film made of low dextrose
equivalent  maltodextrins containing nicotine hydrogen tartrate salt.  maltodextrins with
two different  dextrose dextrose 6 , dextrose12  were selected in order to evaluate the
effect  of  polymer  molecular  weight  on  film  tensile  properties.  The  bitterness  and
astringency intensity of hydrogen tartrate salt and the suppression effect of several taste-
masking agent were evaluated by a Taste-Sensing System. The films were characterised
in term of hydrogen tartrate salt content, tensile properties, and disintegration time and
drug dissolution test. As expected, placebo films made of maltodextrins DE 6 appeared
stiffer  and  less  ductile  than  film  prepared  using  maltodextrins  DE  12.  The  films
disintegrated  within  10  s.  Among the  tested  taste-masking  agent,  the  milk  and  mint
flavours  resulted particularly suitable to mask the taste  of  hydrogen tartrate salt.  The
addition of and taste-masking agents affected film tensile properties; however, the effect
of the addition of hydrogen tartrate salt these components can be counterweighted by
Ultra College Of Pharmacy Page 20
                                                                                 LITERATURE REVIEW
modulating  the  glycerine  content  and/or  the  maltodextrins   molecular  weight.  The
feasibility of hydrogen tartrate salt loaded fast-dissolving films was demonstrated (38)
Doaa Ahmed El-Setouhy. ,  (2010) the present investigation was undertaken with the
objective  of  formulating  orodispersible  film(s)  of  the  antidepressant  drug  tianeptine
sodium to elderly and pediatric patients. The novel film former, lycoat NG73 (granular
hydroxypropyl starch), along with different film-forming agents (hydroxypropyl methyl
cellulose,  hydroxyethyl  cellulose,  and  polyvinyl  alcohol),  in  addition  to  three  film
modifiers;  namely,  maltodextrin,  polyvinyl  pyrrolidone  K90  and  lycoat  RS780
(pregelatinized hydroxypropyl starch) were evaluated. Eight formulae w ere prepared by
the  solvent-casting  method;  and  were  evaluated  for  their  in  vitro  dissolution
characteristics, in vitro disintegration time, and their physico-mechanical properties. The
promising orodispersible film based on lycoat ; showing the greatest drug dissolution,
satisfactory  in  vitro  disintegration  time  and  physico-mechanical  properties  that  are
suitable for orodispersible films (26)
Renuka Mishra et al., (2010) in the present study, rapidly dissolving films of cetirizine
hydrochloride were formulated using pullulan as film forming polymer.Solvent casting
was the method used for formation of rapidly dissolving films. The rapidly dissolving
films were evaluated for  the effect  of type of  casting surface  and plasticizer  on film
separation and taste masking properties.. Cetirizine hydrochloride being slightly bitter,
taste masking was achieved by use of sweeteners, flavours and citric acid. The  in vitro
and in vivo disintegration time of the optimized batch was found to be 30 seconds and 20
seconds respectively.  The films exhibited satisfactory thickness, mechanical properties
like tensile strength, % elongation and elastic modulus (37)
Nidhi P. Sapkal et al., (2011)  developed oral thin films of Ambroxol hydrochloride, a
mucolytic  agent  and  to  investigate  the  effect  of  the  formulation  variables  like
concentration of film forming polymer, emulsifying agent and plasticizer on the physico
chemical properties and in vitro dissolution studies. Hydroxylpropyl methylcellulose was
used as a film former, Tween 80 as an emulsifying agent and polyethylene glycol 4000 as
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a plasticizer. The role of Hydroxylpropyl methylcellulose in deciding thefilm properties
was  significant.  It  affected  folding  endurance,  tensile  strength,  percent  moisture
absorption,  disintegration time and in  vitro  dissolution rate  significantly.  polyethylene
glycol 4000 also found to play a role in deciding the properties of films. The film that
contained Hydroxylpropyl methylcellulose (15 mg /film i.e. 2x3 cm2) in low levels and
Tween 80 (5 mg/film i.e. 2x3 cm2) and polyethylene glycol 4000 (8 mg/film i.e. 2x3
cm2)  in  high  levels  was  found  to  be  suitable  for  film  formation  with  desirable
physicochemical properties, faster disintegration and optimum in vitro release (38)
Sumitha et al., (2011) developed oral films of Seldinafil citrate using Hydroxy propyl
methyl cellulose. Films were prepared by solvent casting method. Polacriline potassium,
an ion exchange resin was used to mask the bitter taste of the drug by forming a complex
with the drug, although the exact mechanism is yet to be determined. Glycerol, menthol
and sucralose were incorporated in the drug containing films as plasticizer, cooling agent
and  sweetener,  respectively.The  films  were  evaluated  for  hydration  study,  folding
endurance and in-vitro  drug dissolution in the distilled water. The films showed neutral
surface pH when prepared using 0.1 N Hydrochloric acid as a solvent.The bitter taste of
the drug was masked by using Polacriline potassium and menthol accompanied by the
synergistic  effect  of  glycerol.  The  films  containing the  higher  proportion  of  glycerol
showed higher water uptake and faster drug release at all the sampling time in the in-vitro
dissolution test.  Optimum plasticity was obtained using the required concentration of
Hydroxypropylmethylcellulose  and  glycerol.  The  study  revealed  that  taste  masked
Seldinafil citrate films can be developed by the selection of appropriate film former and
by the use of auxiliary excipients (39).
Samta et al., (2011) this aim of the present study was to optimize the formulation of fast
dissolving  films  made  of  pullulan  polymer.  The  films  formed  from  solvent  casting
method and subsequent evaporation of solvent resulted in pullulan forming a circular
film. Pullulan was used as film forming agent due to excellent film forming property.
Propylene glycol, glycerine were used as plasticizers. Increasing pullulan concentration
in  formulation  resulted  in  thick  films  as  compared  to  lower  concentration  of  same.
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Thickness of the film was controlled by adjusting the concentration of polymer. Higher
concentration of polymer and plasticizer results in increase in-vitro disintegration time
and in-vitro dissolution time of films. Propylene glycol forms white colored films i.e.
translucent films. Films containing glycerin takes longer time to dry than films containing
propylene  glycol.  Lower  concentration  of  pullulan  and  propylene  glycol  showed
optimum performances (40).
Yellanki  et  al.,  (2011)  an  attempt  to  develop  and  evaluate  mouth-dissolving film of
phenobarbital for quick effect in treatment of epilepsy occurring in pediatric population
has been made in the present study. Suitable film formers and plasticizers are selected
based  on  optimization  studies.  Effect  of  superdisintegrants  in  formulation  of  mouth
dissolving films at different concentrations has been investigated. Films were prepared by
solvent  casting  method.  The  prepared  films  were  evaluated  for  physicochemical
parameters,  in  vitro  disintegration  and  dissolution  time,  in  vitro  release  rate  study,
stability study, and in vivo animal safety study. The best formulation was found to be F3
showing 96.57% drug release in 14 min, following first-order kinetics.In vivo studies in
hamster reports effective and safe use of formulation in animals (41)
Raju et al ,.(2011)  Formulate and evaluate fast dissolving oral films of metoclopramide
which  is  an  excellent  antiemetic  drug.Which  is  used  in  the  treatment  of  emesis  in
paediatrics. Two metoclopramide film were prepared by solvent casting technique using
two  water  soluble  polymers,  hydroxypropyl  methyl  cellulose,  and  carboxy  methyl
cellulose.  Infrared  analysis  revealed  no  interaction  between  Metoclopramide  and
polymers.  The  prepared  films  were  evaluated  for  their  thickness  uniformity,  folding
endurance,  weight  uniformity,  content  uniformity,  surface  pH  and  In-vitro  release.
Formulation  F1  released  99.40% of  drug  within  30  sec  and  was  considered  as  best
formulation. This case study showed that hydroxypropyl methyl cellulose was the most
suitable  film-forming  material  for  metoclopramide  -loaded  films,  providing  fast
dissolution films that were not sticky and were easy to handle (42).
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Ajaykumar  Patil  et  al,.(2011) Fast  dissolving  films  of   Montelukast  sodium  were
prepared  by  solvent  casting  method  using  Hydroxy  propyl  methyl  cellulose  as  film
polymer  with  different  concentrations  of  superdisintegrants  like  microcrystalline
cellulose  and  crospovidone.  Poly  ethylene  glycol  400  is  used  as  plasticizer.  The
physicochemical  parameters  of  the  fast  dissolving  films  were  evaluated.  Infrared
spectroscopy is done for compatability study. In vitro dissolution studies and mechanism
of drug release was identified. The formulation F2 and F5 with 4% of crospovidone and
10% microcrystalline cellulose respectively shows a maximum cumulative percentage
drug release of 97.42% and 94.64% at the end of 30 min respectively. (43).
Gupta et al., (2011) the aim of work to rapidly release the drug   when it is  placed in the
mouth.  These  dosage  forms  are  mostly  preferred  for  pediatric  and  geriatric  patients
because these are not associated with fear of choking. The fast dissolving films prepared
by solvent casting method with suitable appearance, mechanical strength, peel ability and
disintegration  time  were  obtained  using  Methocel  E-5  as  a  primary  film  former.
Meclizine Hydrochloride, a poorly water soluble and bitter drug could be successfully
incorporated in the fast dissolving films with the help of solubilizers such as β-Cyclo
dextrine and Polyethylene glycol-400(44) .
Prasanthi  et  al.,  (2011) Formulate   a  novel  fast  dissolving  drug delivery system of
Salbutamol  suphate.  The  fast  dissolving  films  were  prepared  by  solvent  evaporation
technique  using  different  water-soluble  polymers  (hydroxy  propyl  methylcellulose,
hydroxy propyl cellulose and Sodium Alginate). In this study Tween 80  and Aspartane
used as  solubilizing agent and sweetener respectively.The prepared films were evaluated
for  thickness,  uniformity in  drug content,  folding endurance,  and  disintegration time,
swelling  index,  moisture  loss,  in-vitro  drug  release  studies  and  drug-polymer
compatibility studies.The prepared films were clear, transparent and smooth surface. Film
containing  hydroxy  propyl  methylcellulose  (2%w/w),  Tween  80  (0.5%w/w)  and
Aspartame  (0.5%  w/w)  showed  optimum  performance  against  all  other  prepared
formulations (45).
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 Narasimharao et al., (2011) formulate and evaluate the rapidly dissolving Etophylline
filims, which is a bronchodilator used in treatment of asthma Many pediatric and geriatric
patients are unwilling to the take this solid preparations due to fear of choking. In order to
assist these patients, several fast-dissolving drug delivery system have been developed
Some of the drugs even take a very long time to dissolve, therefore the drug even take
much longer time to show its activity, hence our work is aimed to fast dissolution of the
drug and maximum bioavailability of bronchodilator Etophylline drug by forming a thin
films which are administered orally(46) .
Dhagla  Ram  Choudhary  et  al.,  (2011) Fast  dissolving  films  of  Ondansetron
Hydrochloride  were  prepared  by  solvent  casting  technique  using  carboxy  methyl
cellulose, hydroxy propyl cellulose, and hydroxy propyl methyl cellulose as film forming
polymers. β – Cyclodextrin, neotame and citric acid were employed to mask the bitter
taste  of  Ondansetron  hydrochloride.  The  prepared  films  were  subjected  to
characterization  for  mechanical  properties.  Disintegration  time,  drug  release  pattern,
mouth  dissolving  time  and  content  uniformity  were  also  evaluated..  Films  with  3%
hydroxyl propyl methyl cellulose and 10% w/w propylene glycol showed better results as
compare to hydroxyl propyl cellulose and carboxy methyl cellulose. Films showed good
mechanical properties like, tensile strength,folding endurance and percentage elongation
in comparision to other films prepared by using hydroxyl propyl cellulose and carboxy
methyl cellulose. Films were disintegrated in time of 23 sec and dissolved in time of 55
sec.  These results  suggest  that  hydroxyl  propyl  methyl  cellulose is  an  excellent  film
former,that has shown rapid drug release (80% in 120 sec) amongst different cellulose
derivatives used to prepared films(47). 
Sapkal  NP et.al,(2011) have  developed  fast  dissolving  oral  thin  films  of  Ambroxol
Hydrochloride  and  effect  of  formulation variables  like  concentration of  film forming
polymer  was  investigated.  Also  the  effect  of  emulsifying  agent  and  plasticizer  on
physicochemical properties and in vitro dissolution studies were identified. HPMC was
used as a film former, tween 80 as emulsifying agent and PEG 400 as plasticizer49
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Ghorwade  et  al,(2011)have  formulated  and  evaluated  fast  dissolving  films  of
Montelukast sodium by solvent casting method using HPMC as film base with different
concentrations  of  superdisintegrants  like  microcrystalline  cellulose  and  crospovidone
using PEG 400 as plasticizer. The physicochemical parameters of the fast dissolving films
were  evaluated.  In  vitro  dissolution  studies  and  mechanism  of  drug  release  were
identified.24
Joshi et.al,(2012) have  formulated  and  evaluated  mouth  dissolving  films  of
Domperidone. The solid dispersions of domperidone were prepared with the use of β-
cyclodextrins  in  various  ratios  (1:1,1:2,1:3)  and  solubility  study  was  performed  to
determine  in  which  domperidone  solubility  was  highest.  The  film  was  prepared  by
solvent casting technique utilizing HPMC E15 as film forming agent and PEG 400 as
plasticizer. The formulations were evaluated for their thickness, folding endurance, drug
content, in vitro disintegration time and in vitro dissolution studies.25
Shelke  et  al,(2012) have  formulated  and  evaluated  rapidly  disintegrating  films  of
amlodipine besylate.  Fast  dissolving film of Amlodipine Besylate was prepared using
sodium  alginate  as  film  forming  polymer.  To  decrease  the  disintegration  time  of
formulations, sodium starch glycolate was used as disintegrating agent. The formulations
were evaluated for their thickness, folding endurance, drug content, in vitro disintegration
time and in vitro dissolution studies.48
Bhanushali  et  al  (2011),have  formulated  and  evaluated  mouth  dissolving  tablet  of
isosorbide mononitrate. The superdisintegrant used was crospovidone. The tablets were
evaluated for weight variation, hardness, friability, wetting time, water absorption ratio,
disintegration time and  dissolution study.tablets  were  prepared  by direct  compression
method.  Here  the  disintegration  and  dissolution  rate  of  isosorbide  mononitrate  was
enhanced to great extent by addition of superdisintegrants.27
Pahade et al,(2010) have formulated and developed bilayer sustained release tablets of
isosorbide  mononitrate. The  tablets  were  prepared  by  wet  granulation  method.
Hydrophilic and hydrophobic matrix materials such as hydroxypropyl methylcellulose,
and polyox were used, which can release the drug up to 24hrs in predetermined rate.
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Binder used was pvp k-30. The influence of hydrophilic and hydrophobic polymer and
granulation technique was studied.23
Margret  et  al,(2012)  have  formulated  and  evaluated  sustained  release  tablet  of
isosorbide-5-mononitrate by porous osmotic technology.wet granulation technique was
used. The coating solutions were prepared by using various polymers and pore formers.
The drug release was found to be more with PVP than with HPMC, Ethyl Cellulose and
PEG4000. Compatibility evaluation was performed by FT-IR spectroscopy analysis. The
study implies that the drug and polymers were compatible with each other. 28 
Panchal et al,(2012)have formulated and evaluated mouth dissolving films of Ropinirole
Hydrochloride by using pullulan polymers for a very quick onset of action. The films
were prepared by using polymers  such as  pullulan and  PEG 400 as  plasticizer,  by a
solvent casting method. A marked increase in the % drug release was exhibited by mouth
dissolving films of Ropinirole Hydrochloride containing pullulan as a polymer at 60 sec,
when  compared  to  other  polymers  films.  Mouth  dissolving  films  of  Ropinirole
Hydrochloride containing pullulan showed better tensile strength.29
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3. SCOPE, OBJECTIVE AND PLAN OF THE WORK
3.1 SCOPE
           Isosorbide mononitrate relaxes vascular smooth muscles by stimulating cyclic-
GMP. It decreases left ventricular pressure (preload) and arterial resistance (after load).(22)
Isosorbide mononitrate is a nitrate-class drug used for the prophylactic treatment
of angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence
of angina.  Research on isosorbide mononitrate as a cervical ripener to reduce time at
hospital to birth is supportive.
It is available in the USA by Kremers Urban under the trade name Monoket, and 
marketed in the UK under the trade names: Monosorb, Chemydur. In India, this drug is 
available under the brand names of Ismo, Isonorm, Monotrate, Solotrate, and Monit. 
Isosorbide mononitrate is available as 10 mg and 20 mg of immediate release tablets. But 
it is not available as an orally disintegration dosage form. 
 Isosorbide mononitrate film formulation is useful for bedridden and geriatric pa-
tient with Angina pectoris who are unwilling to take solid dosage form. Hence an effort 
was taken to formulate Isosorbide mononitrate as a mouth dissolving film.
   3.2 Objectives 
The main objective of present work is to formulate and evaluate  fast dissolving oral thin
film of Isosorbide mononitrate with the use of polymers like HPMC and PVA for the
treatment of angina pectoris. 
3.3 Plan of Work
1) Literature studies
2) Analytical method development
 Construction of standard curve for Isosorbide mononitrate
3) Preformulation studies
   Drug polymer computability by FTIR studies.
4) Formulation of Fast dissolving oral films.
  Selection of polymer
 Optimization of polymer concentration
 Preparation of film by solvent casting method.
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5) Evaluation of fast dissolving films
 Physical appearance and surface texture of film
 Weight variation.
 Thickness of film.
 Tensile strength.
 Percentage elongation
 Folding endurance.
 Surface pH.
 Dispersion time
 Disintegrating time
 Invitro drug release study
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4. MATERIALS AND INSTRUMENTS
                                             4.1 LIST OF MATERIALS
S.No Chemicals and reagents Supplier
1 Isosorbide mononitrate RA CHEM Pharma, Hyderabad
2
Hydroxy propyl methyl cellulose 5cps 
(Hyperomellose)
S.D.Fine chem Ltd. Mumbai
3
Poly vinyl alcohol(Medium viscosity; 
Molecular weight: 1,25000)
S.D.Finechem Ltd. Mumbai
4 Sucralose S.D Finechem Ltd. Mumbai
5 Pineapple Flavour
6 Glycerine Vama pharma. Nagpur
                                     
   Table No.3, List of Materials
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4.2 List of Instrument Used                                 
                  
4.3  
DRUG 
PROFILE
ISOSORBIDE MONONITRATE
 Structure: -          
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Sr.no. Name of instrument/ Equipments Manufacture
1 Electronic balance(BL-2200H) Shimadzu corporation
2 pH-meter Universal biochemals
3 Dissolution apparatus Lab India Disso-2000
4
UV-Visible double beam 
spectrophotometer
Systronic 118
5 Bath Ultrasonicator Life care
6 FTIR spectrophotometer Perkin Elmer
7 Desiccator
Qualigens Fine Chem. 
Mumbai
8 Dial gauge
Baker Precision 
measuring instruments 
9 Magnetic stirrer (2MLH)
Remi equipment Pvt. Ltd. 
Mumbai
11 Heating  mantle Guna enterprises, Chennai
12 Vacuum oven
Shavani scientific Pvt. 
Ltd. Bombay
   13 TA.XT plus Texture analyser Stable Microsystems, U.K
14 Microwave oven Magic cook, Whirlpool
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Formula :  C6H9NO6
IUPAC Name                                  :8-nitrooxy-2,6-dioxabicyclo[3.3.0]octan-4-Ol  
BCS Class                                 : Class 1
Molecular Weight                         :    191.14 g/mol
 pka (dissociation constant)          :    -3.9
 Category                                        : Anti Anginal, Vasodilator Agents
 Description                                      :   Colourless prismatic crystals
 Solubility                                        :   Soluble in water, methanol, ethanol and 
chloroform
                                                                         
                                                                                                                                                                                            
 Melting Point                                     : 89°C
 Partition coefficient (logP)                     : -0.2
 Volume of distribution                   :  0.6 to 0.7 L/kg.
Protein binding                                 :  Plasma protein binding is <5%
 Mechanism of Action
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 Isosorbide  Mononitrate  is  converted  to  nitric  oxide  (NO),  an  active  intermediate
compound  which  activates  the  enzyme  guanylate  cyclase  (Atrial  natriuretic  peptide
receptor  A).  This  stimulates  the  synthesis  of  cyclic  guanosine  3',5'-monophosphate
(cGMP) which then activates a series of protein kinase-dependent phosphorylations in the
smooth muscle cells, eventually resulting in the dephosphorylation of the myosin light
chain of the smooth muscle fiber. The subsequent release of calcium ions results in the
relaxation of the smooth muscle cells and vasodilation.
Pharmacodynamics
Dosing  regimens  for  most  chronically  used  drugs  are  designed  to  provide  plasma
concentrations  that  are  continuously greater  than a minimally effective concentration.
This strategy is inappropriate for organic nitrates. Several well-controlled clinical trials
have used exercise testing to assess the antianginal efficacy of continuously delivered
nitrates. In the large majority of these trials, active agents were indistinguishable from
placebo after 24 hours (or less) of continuous therapy. Attempts to overcome tolerance by
dose escalation,  even  to  doses  far  in  excess  of  those used  acutely,  have  consistently
failed. Only after nitrates have been absent from the body for several hours has their
antianginal efficacy been restored. 
 Pharmacokinetics:- 
Absorption/ Distribution
Isosorbide-5-mononitrate  is  rapidly  and  completely  absorbed  from  the  conventional
dosage forms. Unlike isosorbide dinitrate, isosorbide mononitrate is free from first-pass
metabolism in  the liver,  and its  bioavailability therefore shows lower inter-individual
variability. AUC values assessed by reference to the plasma levels increase linearly with
the dose. With Corangin, the peak concentrations attained are approximately 60% lower
than  after  administration  of  the  same  dose  in  conventional  dosage  forms.  Peak
concentrations are reached 4-8 hours after ingestion of Corangin and in less than 1 hour
after administration of conventional formulations. The amount absorbed from sustained-
release formulations such as Corangin is slightly reduced (by 10-20%) in comparison
with conventional formulations. No accumulation of isosorbide-5-mononitrate was seen
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after repeated once-daily administration in normal volunteers or in patients. The results of
pharmacokinetic studies suggest that no alterations of the dosage should be necessary in
patients with coronary heart disease, renal failure, or hepatic cirrhosis. Ingestion of food
has  been reported to  have  only a  negligible effect  on the absorption of  isosorbide-5-
mononitrate.The volume of distribution of isosorbide mononitrate is approximately 0.6
L/kg, which is close to the total body water. The plasma protein binding of isosorbide
mononitrate is negligible.
Metabolism
Isosorbide  mononitrate  is  almost  completely  metabolized  in  the  liver.  The  resulting
metabolites are inactive.
Elimination 
Isosorbide mononitrate  is  excreted  via the kidneys  almost  exclusively in  the form of
metabolites. Approximately 2% is excreted via the kidneys in unchanged form. Mean half
lives  of  isosorbide-5-mononitrate  calculated  after  administration  of  conventional
formulations range between 4.0 and 4.8 hours.
Contraindications
Isosorbide  Mononitrate  Extended-Release  Tablets  are  contraindicated  in  patients  who
have shown hypersensitivity or idiosyncratic reactions to other nitrates or nitrites
Drug interactions
The vasodilating effects of Isosorbide Mononitrate may be additive with those of other
vasodilators.  Alcohol,  in  particular,  has  been found to  exhibit  additive effects  of  this
variety.
Marked symptomatic orthostatic hypotension has been reported when calcium channel
blockers and organic nitrates were used in combination. Dose adjustments of either class
of agents may be necessary.
Therapeutic uses
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Isosorbide  mononitrate  is  a nitrate class  drug  used  for  the  prophylactic  treatment  of
angina pectoris; that is, it is taken in order to prevent or at least reduce the occurrence of
angina.
Adverse Reactions
Autonomic Nervous System Disorders: Dry mouth, hot flushes.
Body  as  a  Whole: Asthenia,  back  pain,  chest  pain,  edema,  fatigue,  fever,  flu-like
symptoms, malaise, rigors.
Cardiovascular Disorders, General: Cardiac failure, hypertension, hypotension.
Central  and  Peripheral  Nervous System Disorders: Dizziness,  headache,  hypoesthesia,
migraine, neuritis, paresis, paresthesia, ptosis, tremor, vertigo.
Gastrointestinal  System Disorders: Abdominal  pain,  constipation,  diarrhea,  dyspepsia,
flatulence, gastric ulcer, gastritis, glossitis, hemorrhagic gastric ulcer, hemorrhoids, loose
stools, melena, nausea, vomiting.
Hearing and Vestibular Disorders: Earache, tinnitus, tympanic membrane perforation.
Heart  Rate  and  Rhythm  Disorders: Arrhythmia,  arrhythmia  atrial,  atrial  fibrillation,
bradycardia,  bundle  branch  block,  extrasystole,  palpitation,  tachycardia,  ventricular
tachycardia.
Liver and Biliary System Disorders: SGOT increase, SGPT increase.
Metabolic and Nutritional Disorders: Hyperuricemia, hypokalemia.
Musculoskeletal  System  Disorders: Arthralgia,  frozen  shoulder,  muscle  weakness,
musculoskeletal pain, myalgia, myositis, tendon disorder, torticollis.
Myo-,  Endo-,  Pericardial  and  Valve  Disorders: Angina  pectoris  aggravated,  heart
murmur, heart sound abnormal, myocardial infarction, Q wave abnormality.
Platelet, Bleeding and Clotting Disorders: Purpura, thrombocytopenia.
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Psychiatric  Disorders: Anxiety,  concentration  impaired,  confusion,  decreased  libido,
depression, impotence, insomnia, nervousness, paroniria, somnolence.
Red Blood Cell Disorder: Hypochromic anemia.
Reproductive Disorders, Female: Atrophic vaginitis, breast pain.
Resistance Mechanism Disorders: Bacterial infection, moniliasis, viral infection.
Respiratory System Disorders: Bronchitis, bronchospasm, coughing, dyspnea, increased
sputum, nasal congestion, pharyngitis, pneumonia, pulmonary infiltration, rales, rhinitis,
sinusitis.
Skin  and  Appendages  Disorders: Acne,  hair  texture  abnormal,  increased  sweating,
pruritus, rash, skin nodule.
Urinary System Disorders: Polyuria, renal calculus, urinary tract infection.
Vascular (Extracardiac) Disorders: Flushing, intermittent claudication, leg ulcer, varicose
vein.
Vision Disorders: Conjunctivitis, photophobia, vision abnormal.
Overdosage
Hemodynamic Effects
The ill effects of Isosorbide Mononitrate overdose are generally the result of Isosorbide
Mononitrate's capacity to induce vasodilatation, venous pooling, reduced cardiac output,
and  hypotension.  These  hemodynamic  changes  may  have  protean  manifestations,
including  increased  intracranial  pressure,  with  any  or  all  of  persistent  throbbing
headache,  confusion,  and  moderate  fever;  vertigo,  palpitations;  visual  disturbances;
nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially
in the upright posture); air hunger and dyspnea, later followed by reduced ventilatory
effort;  diaphoresis,  with the skin either flushed or  cold and clammy;  heart  block and
bradycardia; paralysis; coma; seizures and death.
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Methemoglobinemia
Methemoglobinemia has been reported in patients receiving other organic nitrates, and it
probably could also occur as a side effect of Isosorbide Mononitrate. Certainly nitrate
ions liberated during metabolism of Isosorbide Mononitrate can oxidize hemoglobin into
methemoglobin.  Even  in  patients  totally  without  cytochrome  b5 reductase  activity,
however,  and  even  assuming  that  the  nitrate  moiety  of  Isosorbide  Mononitrate  is
quantitatively  applied  to  oxidation  of  hemoglobin,  about  2  mg/kg  of  Isosorbide
Mononitrate  should  be  required  before  any  of  these  patients  manifest  clinically
significant  (≥10%)  methemoglobinemia.  In  patients  with  normal  reductase  function,
significant production of methemoglobin should require even larger doses of Isosorbide
Mononitrate.  In  one  study  in  which  36  patients  received  2-4  weeks  of  continuous
nitroglycerin therapy at 3.1 to 4.4 mg/hr (equivalent, in total administered dose of nitrate
ions, to 7.8-11.1 mg of Isosorbide Mononitrate per hour),  the average methemoglobin
level measured was 0.2%; this was comparable to that observed in parallel patients who
received placebo.
Dosage 
The recommended starting dose of Isosorbide Mononitrate  is 30 mg once daily. After
several days, the dosage may be increased to 120 mg once daily. Rarely, 240 mg may be
required. The daily dose of Isosorbide Mononitrate should be taken in the morning on
arising. (21)
4.4 POLYVINYL ALCOHOL(22)
Nonproprietary Names 
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 PhEur: Poly (vinylis acetas) 
 USP: Polyvinyl alcohol 
Synonyms:  Airvol; Alcotex; Elvanol; Gelvatol; Gohsenol; Lemol; Mowiol; Polyvinol; 
PVA, vinyl alcohol polymer.
Chemical Name: Ethenol, homopolymer
Empirical Formula: (C2H4O)n
Molecular Weight: 20 000–200 000
Polyvinyl  alcohol is  a water-soluble synthetic polymer represented by the formula
(C2H4O)n. The value of n for commercially available materials lies between 500 and
5000, equivalent to a molecular weight range of approximately (20 000–200 000)
Structural Formula:
Description:  Polyvinyl  alcohol  occurs  as  an  odorless,  white  to  cream-colored
granular powder.
Melting point: 228°C for fully hydrolyzed grades; 
180–190°C for partially hydrolyzed grades. 
Functional Category:  Coating agent; lubricant; stabilizing agent; viscosity-increasing
agent.
Solubility
Soluble in  water;  slightly soluble  in  ethanol  (95%);  insoluble  in  organic  solvents.
Dissolution requires dispersion (wetting) of the solid in water at room temperature
followed by heating the mixture to about 90°C for approximately 5 minutes. Mixing
should be continued while the heated solution is cooled to room temperature.
Specific gravity:
1.19–1.31 for solid at 25°C; 
1.02 for 10% w/v aqueous solution at 25°C. 
Specific heat: 1.67 J/g (0.4 cal/g)
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Grade
Dynamic viscosity of 4% w/v aqueous
solution at 20°C (mPa s)
High viscosity 40.0–65.0
Medium viscosity 21.0–33.0
Low viscosity 4.0–7.0
 Table No.5 Viscosity of commercial grades of polyvinyl alcohol.
Applications in Pharmaceutical Formulation or Technology:
Polyvinyl  alcohol  is  primarily  used  in  topical  pharmaceutical  and  ophthalmic
formulations;  it  is  a  stabilizing agent  for  emulsions  (0.25–3.0% w/v).  For  viscous
formulations  such  as  ophthalmic  products  Polyvinyl  alcohol  is  also  used  as  a
viscosity-increasing agent. It is used in contact lens and artificial tears solutions for
lubrication purposes. Polyvinyl alcohol may be made into microspheres when mixed
with a glutaraldehyde solution. It is also used in transdermal patches.
Stability and Storage Conditions:
Polyvinyl  alcohol  is  stable  in  cool,  dry  place  when  it  is  stored  in  tightly  sealed
container.  Aqueous  solutions  are  stable  in  corrosion-resistant  sealed  containers.
Preservatives needed to the solution if extended storage is required. Polyvinyl alcohol
slow degradation undergoes at temperature 100°C and rapid degradation at 200°C; it
is stable on exposure to light.
Incompatibilities:
Polyvinyl alcohol undergoes reactions typical of a compound with secondary hydroxy
groups, such as esterification. It decomposes in strong acids, and softens or dissolves
in weak acids and alkalis. It is incompatible at high concentration with inorganic salts,
especially sulfates and phosphates; precipitation of polyvinyl alcohol 5% w/v can be
caused by phosphates.  Gelling of polyvinyl alcohol solution may occur if  borax is
present.
Safety
Polyvinyl  alcohol  is  a  nontoxic  material.  It  is  nonirritant  to  the  skin  and  eyes  at
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concentrations up to 10%; concentrations up to 7% are used in cosmetics.
Studies in rats have shown that polyvinyl alcohol 5% w/v aqueous solution injected
subcutaneously can cause anemia and infiltrate various organs and tissues. 
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of material
handled. Eye protection and gloves are recommended. Polyvinyl alcohol dust may be
an irritant on inhalation. Handle in a well-ventilated environment.
4.5  HYDROXYPROPYL METHYLCELLULOSE(22)
Non-proprietary Names     :        BP: Hypromellose
JP: Hydroxypropylmethylcellulose
PhEur: Hypromellosum
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USP: Hypromellose 
                                                         
Synonyms    :   Benecel  MHPC;  E464;  hydroxypropyl
methylcellulose;  HPMC;  Methocel;  methylcellulose  propylene  glycol  ether;  methyl
hydroxypropylcellulose; Metolose; Tylopur. 
Chemical Name    :   Cellulose hydroxypropyl methyl ether  
Description                : Hypromellose is an odorless and tasteless, white or
creamy white fibrous or granular powder
Structural formula             :
Functional Category        :   Coating  agent;  film-former;  rate-controlling
polymer  for  sustained  release;  stabilizing  agent;  suspending  agent;  tablet  binder;
viscosity-increasing agent. 
Typical Properties: 
Density (bulk)    : 0.341 g/cm3
Density (tapped)    :         0.557 g/cm3
Density (true)    :        1.326 g/cm3
Melting point    :  browns at 190–200oC; chars at 225–230oC
Solubility    :  Easily  dispersed  in  water  at  all  temperatures
forming  clear,  colloidal  solutions.  The  Aqueous  solubility  varies  with  the  degree  of
substitution.
Practically  insoluble  in  acetone,  ethanol  (95%),
ether, and toluene.
Stability and Storage Conditions
 Hypromellose  powder  is  a  stable  material,  although  it  is  hygroscopic  after  drying.
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions.
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Hypromellose undergoes a reversible sol–gel transformation upon heating and cooling,
respectively. The gel point is 50–908C, depending upon the grade and concentration of
material.  Aqueous  solutions  are  comparatively  enzyme-resistant,  providing  good
viscosity stability during long-term storage.  However,  aqueous solutions  are liable to
microbial spoilage and should be preserved with an antimicrobial preservative:
when  hypromellose  is  used  as  a  viscosity-increasing  agent   in  ophthalmic  solutions,
benzalkonium chloride is commonly used as the preservative.  Aqueous solutions may
also be sterilized by autoclaving; the coagulated polymer must be redispersed on cooling
by shaking. Hypromellose powder should be stored in a well-closed container, in a cool,
dry place.
Incompatibilities
Hypromellose  is  incompatible  with  some  oxidizing  agents.  Since  it  is  nonionic,
hypromellose will not complex with metallic salts or ionic organics to form insoluble
precipitates.
Safety
Hypromellose  powder  is  a  stable  material,  although  it  is  hygroscopic  after  drying.
Solutions are stable at pH 3–11. Increasing temperature reduces the viscosity of solutions.
Hypromellose undergoes a reversible sol–gel transformation upon heating and cooling,
respectively. The gel point is 50–908C, depending upon the grade and concentration of
material.  Aqueous  solutions  are  comparatively  enzyme-resistant,  providing  good
viscosity stability during long-term storage.  However,  aqueous solutions  are liable to
microbial  spoilage  and should be preserved with  an antimicrobial  preservative:  when
hypromellose  is  used  as  a  viscosity-increasing  agent  in  ophthalmic  solutions,
benzalkonium chloride is commonly used as the preservative.  Aqueous solutions may
also be sterilized by autoclaving; the coagulated polymer must be redispersed on cooling
by shaking. Hypromellose powder should be stored in a well-closed container, in a cool,
dry place.
 Applications
Hypromellose  is  widely  used  in  oral,  ophthalmic  and  topical  pharmaceutical
formulations. In oral products, hypromellose is primarily used as a tablet binder, in film-
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coating, and as a matrix for use in extended-release tablet formulations. Concentrations
between 2% and 5% w/w may be used as  a binder  in either  wet-  or  dry-granulation
processes. High-viscosity grades may be used to retard the release of drugs from a matrix
at levels of 10–80% w/w in tablets and capsules. Depending upon the viscosity grade,
concentrations of 2–20% w/w are used for film-forming solutions to film-coat tablets.
Lower-viscosity grades are used in aqueous film-coating solutions, while higher-viscosity
grades  are  used  with  organic  solvents.  Examples  of  film-coating  materials  that  are
commercially available include AnyCoat C, Spectracel, and Pharmacoat. Hypromellose is
also used as a suspending and thickening agent in topical formulations. Compared with
methylcellulose, hypromellose produces aqueous solutions of greater clarity, with fewer
undispersed fibers present, and is therefore preferred in formulations for ophthalmic use.
Hypromellose at concentrations between 0.45–1.0% w/w may be added as a thickening
agent to vehicles for eye drops and artificial tear solutions. Hypromellose is also used as
an emulsifier, suspending agent, and stabilizing agent in topical gels and ointments. As a
protective colloid, it can prevent droplets and particles from coalescing or agglomerating,
thus  inhibiting  the  formation  of  sediments.  In  addition,  hypromellose  is  used  in  the
manufacture of capsules, as an adhesive in plastic bandages, and as a wetting agent for
hard contact lenses. It is also widely used in cosmetics and food products.
4.6 GLYCERINE(22)
Non proprietary names: BP: Glycerol
USP: Glycerin
PhEur: Glycerolum
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Synonyms:  Croderol;  E422;  glycerine;  Glycon  G-100;  Kemstrene;  Optim; Pricerine;
1,2,3-propanetriol; trihydroxypropane glycerol.
Chemical Name: Propane-1,2,3-triol 
Empirical Formula: C3H8O3
Molecular Weight: 92.09
Structural Formula: 
Functional  Category:  Antimicrobial  preservative;  emollient;  humectant;  plasticizer;
solvent; sweetening agent; tonicity agent
Description
Glycerin is a clear, colorless, odorless, viscous, hygroscopic liquid; it has a sweet taste,
approximately 0.6 times as sweet as sucrose.
Typical Properties
Boiling point: 290oc(with decomposition)
Density: 1.2636 g/cm3 at 20oC
Flash point: 1768C (open cup
Hygroscopicity: hygroscopic.
Melting point: 17.88C
Solubility:Soluble  in  95%  ethanol  ,  methanol,and  water  ,  slightly  soluble  in
acetone,practically insoluble in benzene and chloroform
Applications
Glycerin  is  used  in  a  wide  variety  of  pharmaceutical  formulations  including  oral,
ophthalmic,  topical,  and  parenteral  preparation.In  topical  pharmaceutical  formulations
and cosmetics; glycerin is used primarily for its humectant and emollient properties. In
parenteral formulations, glycerin is used mainly as a solvent.In oral solutions, glycerin is
used as a solvent, sweetening agent, antimicrobial preservative,and viscosity increasing
agent. It is also used as a plasticizer and in film coatings. Glycerin is additionally used in
topical formulations such as creams and emulsions. Glycerin is used as aplasticizer of
gelatin in the production of soft-gelatin capsules and gelatin suppositories. Glycerin is
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employed as a therapeutic agent in a variety of clinical applications, and is also used as a
food additive.
Stability and Storage Conditions
Glycerin is hygroscopic. Pure glycerin is not prone to oxidation by the atmosphere under
ordinary storage conditions but it  decomposes on heating,  with the evolution of toxic
acrolein.Mixtures  of  glycerin  with  water,  ethanol  (95%),  and  propyleneglycol  are
chemically stable. Glycerin may crystallize if stored at low temperatures; the crystals do
not melt until warmed to 208C.Glycerin should be stored in an airtight container, in a
cool, dry place
Incompatibilities
Glycerin may explode if mixed with strong oxidizing agents such as chromium trioxide,
potassium chlorate, or potassium permanganate. In dilute solution, the reaction proceeds
at as lower rate with several  oxidation products being formed. Black discoloration of
glycerin occurs in the presence of light, or on contact with zinc oxide or basic bismuth
nitrate.  An  iron  contaminant  in  glycerin  is  responsible  for  the  darkening  in  color  of
mixtures containing phenols, salicylates,and tannin.Glycerin forms a boric acid complex,
glyceroboric acid, that is a stronger acid than boric acid.
Safety
Glycerin occurs naturally in animal and vegetable fats and oils that are consumed as part
of a normal diet. Glycerin is readily absorbed from the intestine and is either metabolized
to carbon dioxide and glycogen or used in the synthesis of body fats. Glycerin is used in a
wide  variety  of  pharmaceutical  formulations  including  oral,  ophthalmic,  parenteral,
andtopical preparations. Adverse effects are mainly due to the dehydrating properties of
glycerin.)Oral  doses  are  demulcent  and  mildly  laxative  in  action.  Large  doses  may
produce  headache,  thirst,  nausea,  and  hyperglycemia.  The  therapeutic  parenteral
administration of very large glycerin doses,  70–80 g over 30–60 minutes in adults to
reduce cranial pressure, may induce hemolysis, hemoglobinuria,and renal failure) Slower
administration has no deleterious effects.
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of material
handled. Eye protection and gloves are recommended. In the UK, the recommended long-
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term (8-hourTWA) exposure limit for glycerin mist is 10 mg/m3. Glycerinis combustible
and may react explosively with strong oxidizing agents;
4.7 SUCRALOSE(22)
Nonproprietary Names
USPNF: Sucralose
Synonyms: Splenda; TGS; 10, 40, 60-trichlorogalactosucrose; 4,10,60-trichloro-4,10,60-
trideoxy-galacto-sucrose
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Chemical  Name:  1,6-Dichloro-1,6-dideoxy-b-D-fructofuranosyl-4-chloro-4-deoxy-a-D-
galactopyranoside
Structural formulae: 
 Empirical  Formula: C12H19Cl3O8 
Molecular Weight: 397.63 
 Functional Category: Used as a sweetner in pharmaceutical formulations
Description
Sucralose is a white to off-white colored, free-flowing, crystalline Powder.
Typical Properties
Acidity/alkalinity: pH = 5–6 (10% w/v aqueous solution at
208C)
Density (bulk): 0.35 g/cm3
Density (tapped): 0.62 g/cm3
Density (true): 1.63 g/cm3
Melting point: 1308C (for anhydrous crystalline form); 36.5oC
Particle size distribution: 90% < 12 mm in size.
Partition coefficient: log10 P = —0.51 (octanol:water)
Solubility: freely soluble in ethanol (95%), methanol, and water; slightly soluble in ethyl
acetate.
Stability and Storage Conditions
Sucralose is a relatively stable material. In aqueous solution, at highly acidic conditions
(pH < 3), and at high temperatures(4358C), it is hydrolyzed to a limited extent, producing
4-chloro-4-deoxygalactose  and  1,6-dichloro-1,6-dideoxyfructose.In  food  products,
sucralose remains stable throughout extended storage periods, even at low pH. However,
it is moststable at pH 5–6.Sucralose should be stored in a well-closed container in a cool,
dry  place,  at  a  temperature  not  exceeding  218C.  Sucralose,when  heated  at  elevated
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temperatures, may break down with the release of carbon dioxide, carbon monoxide, and
minor amounts of hydrogen chloride.
Safety
Sucralose is generally regarded as a nontoxic and nonirritant material and is approved, in
a number of countries, for use in food products. Following oral consumption, sucralose is
mainly unabsorbed and is excreted in the feces. The WHO has set an acceptable daily
intake for sucralose of up to 15 mg/kg body-weight
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of material
handled.
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5  EXPERIMENTAL METHOD
5.1 Analytical Method of Development
5.1.1 Identification of λmax for Isosorbide Mononitrate
Isosorbide mononitrate accurately weighed and dissolved in purified water and further
diluted  was  made  to  get  the  required  concentration.  The  wave  length  of  maximum
absorbance (λmax) of this clear solution was determined from 200-280nm using distilled
water is used as blank. 
5.1.2 Construction of Standard Curve for Isosorbide mononitrate
Procedure:
5.1.2.1 Preparation of stock solution
100mg of isosorbide mononitrate is weighed and dissolved in 100ml water. From this
solution 1 ml was pipetted out and diluted with water up to 100ml mark as stock solution.
5.1.2.2 Preparation of sample solution:
             Further dilution was carried out to obtain the concentration of 1, 2, 3,4,5,6,7,8,9
and 10 µg/ml respectively. The absorbance was measured at 220 nm against the respec-
tive blank solution using UV visible spectrophotometer Perk-Elmer Lambda 40 P. The
standard curves were plotted by putting the known concentration on X- axis and the ob-
tained absorbance on Y- axis.
5.2 Drug Polymer Compatibility Studies:
 Excipients  are  the  essential  component  of  a  dosage  form.  The formulation  of
stable effective dosage forms depends on the care full selection of the excipient. Infrared
spectroscopy for pure drug Isosorbide mononitrate and polymers used for formulation
were testify to check the intactness of drug and polymer in the formulation using Perkin
Elmer model furrier transform infrared spectrometer by KBr disk method.
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5.4 Preparation of film
5.4 .1 Calculation of dose for Isosorbide mononitrate
The  dose  selected  for  development  is  10mg.  Isosorbide  mononitrate  contains
lactose  monohydrate  by  which  each  12.5mg  contains  10mg  equivalent  Isosorbide
mononitrate.
Film diameter of 2.6 cm was selected for a single dose. Based on the petridish
surface area, amount of drug required was calculated for every batch.
For example petridish with diameter of 8 cm (surface area: 5.31 sq.cm), 118.39
mg of isosorbide mononitrate with lactose was taken.
From the preliminary physical observation of the prepared placebo to optimize
polymer concentration and composition films the best compositions were used for the
incorporation of Isosorbide mononitrate. PVA, HPMC and combination of both PVA and
HPMC was dissolved in water with continuous stirring. Calculated amount of Isosorbide
mononitrate was dissolved in the polymeric solution. After complete dissolution of the
drug,  Sucralose,  pineapple flavor  and glycerin  (plasticizer)  were added and stirred to
form  a  homogeneous  solution.  The  solution  was  casted  in  a  petridish  then  kept  in
microwave oven at  50ºC for 45 minutes. Further drying was computed using vacuum
oven at 350C by applying vacuum. The film thus formed was cut into size of 2.6 cm
diameter.  Each  film contains  12mg of  Isosorbide  mononitrate  equivalent  to  10mg of
Isosorbide mononitrate. The detailed compositions of the Isosorbide mononitrate films
are given in Table
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Formulation
Isosorbide
mononitrate
(mg)
HPMC
(mg)
PVA
(mg)
Glycerine
(mg)
Sucralose
(mg)
Pine
apple
flavour
Purified
Water
(ml)
B1 12.5 200 - 60 50 0.05 ml 5
B2 12.5 _ 250 _ 50 0.05ml 5
B3 12.5 200 250 - 50 0.05ml 5
Table No.6 Composition of Oral Thin Film Formulation
5.5 EVALUATION OF FAST DISSOLVING FILM FORMULATION
      5.5.1 Physical appearance and surface texture of films
These parameters were checked simply with visual infection of films and by feel
or touch. The observation suggests that the films are having smooth surface and they are
elegant enough to see.
5.5.2 Thickness: 
All the batches were evaluated for thickness by using calibrated Thickness gauge
Baker,  typeK17  jeweled  (0.001-  0.1  mm).  Three  samples  from  all  the  batches  was
withdrawn and evaluated for thickness.
5.5.3 Uniformity of weight:
            Each film was weighed individually on electronic balance and average weight of
three films was found.
5.5.4 Folding endurance:
The flexibility of films can be measured quantitatively in terms of what is known 
as  folding  endurance.  Folding  endurance  of  the  films  was  determined  by repeatedly
ULTRA COLLEGE OF PHARMACY Page 46
                                                                                              EXPERIMENTAL METHOD
folding a small strip of the films at the same place till it broke. The number of times films
could be folded at the same place, without breaking gives the value of folding endurance.
5.5.5 Tensile strength
Tensile strength of the films was determined by using Texture Analyzer (Stable micro
system)
 Tensile strength (kg/cm2) = Force at break / Initial cross sectional area of the film
5.5.6 Percentage elongation 
Percentage elongation was calculated by measuring the increase in length of the film after
tensile strength measurement by using the following formula.
Percentage Elongation = [L-L0] X 100 / L0
Where, L was the Final length, L0 was initial length.
5.5.7 Surface pH:
Surface pH was determined by the films were allowed in contact with 1ml of 
distilled water. The surface pH was noted by bringing pH paper near the surface of films.
5.5.8. Drug content
The films were tested for drug content by UV-Spectrophotometric method at 
220nm.A film of 8 cm diameter was dissolved in purified water and diluted to get a 
concentration of 1 µg/ml. The absorbance was measured at 210 nm against blank. The 
amount of drug was calculated using standard graph. The drug content analysis was 
performed in triplicate.
5.5.9.Content Uniformity
Ten  films  were  individually  assayed  for  their  drug  content.  Films  of  2.6  cm
diameter were dissolved in 10 ml water from this 1ml is taken and diluted to 100ml with
water, from this 1ml is withdrawn and make up the volume up to 100ml with water to get
a concentration of 1 µg/ml.The requirements for content uniformity are met if the amount
of the active ingredient in each tablet within the range of 85-115% of the label claims.
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5.5.10. In-vitro Dispersion Time 
In-vitro dispersion time was measured by dropping a in petridish with 6 ml of
water three films from each formulation were randomly selected and in-vitro dispersion
time was performed 
5.5.11 In-vitro dissolution studies
The release study was carried out in a USP dissolution apparatus type VI. The
dissolution medium was 900 ml water maintained at 370C and kept in a glass beaker fixed
inside the USP dissolution flask. The film was fixed to the central axis, which rotated at
50 rpm. Filtered samples (2ml.) were manually collected at 2,5,10,15,20 and 30 min. The
samples  were compensated with  an equal  volume of purified water  kept  at  the same
temperature.  The  concentration  of  drug  released  in  the  medium  was  assayed
spectrophotometrically at 220 nm after suitable dilution with the dissolution medium.
Dissolution parameters
Dissolution Medium : Purified water ,900ml
RPM : 50
Apparatus : Dissolution apparatus Type VI (CylinderApparatus) 
Temperature : 37ºC ± 0.5ºC
Withdrawal time : 2,5,10,15,20,and 30min.
Volume withdraw : 2ml
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6 Analytical Method Development
6.1  Construction of Standard Curve for Isosorbide mononitrate
The wave length of maximum absorbance of drug was found to be 220 nm. Beer lambertz
law obeying range was found to be in the range of 1-10µg/ml at 210 nm against water is used
as blank. 
Table No.6  Standard Curve of Isosorbide mononitrate
Absorbance of Isosorbide mononitrate in Distilled water
CONCENTRATION 
(µg/ml)
ABSORBANCE
1 0.027
2 0.053
3 0.083
4 0.103
5 0.135
6 0.156
7 0.18
8 0.215
9 0.235
10 0.265
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Figure No.3, Calibration Curve for Isosorbide mononitrate in distilled water in 220nm
6.2 Drug-Polymer Compatibility Study
Compatibility studies were performed using FT-IR spectrophotometer. The IR spectrum of
pure drug and physical mixture of drug and polymer were studied by using Perkin Elmer
model furrier transform infrared spectrometer by KBr disk method.
The peaks obtained in  the spectra  of  each formulation correlates  with  the peaks  of  drug
spectrum. This indicates that the drug is compatible with the formulation components. The
spectra for all formulations are shown below.
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                                 Figure No : 4 , FTIR studies for Isosorbide mononitrate  
  
Wave number cm-1 Characteristic band
3221.87 C-H alkyne
2914.82 C-H stretching
1458.88 -NO2
1904.34 C-O-C stretching
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                 Figure No: 5, FTIR Studies for Hydroxy propyl methyl cellulose
    
Wave number in cm-1 Characteristic band
3466.89 OH stretching
2933.03 C-H stretching
1655.18 C-O stretching
1465.82 C-H deformation
944.64 C-H deformation
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   Figure No: 6, FTIR studies for Poly vinyl alcohol
Wave number in cm-1 Characteristic band
3452.33 O-H stretching
1582.79 C=C stretching
1093.99 C-C stretching
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Figure  No.7,  FTIR Studies  for Isosorbide  mononitrate  and  Hydroxy  propyl  methyl
cellulose
Wave number in cm-1 Characteristic band
3221.87 C-H alkyne
2914.82 C-H stretching
1904.34 C-O-C stretching
3466.89 OH stretching
2933.03 C-H stretching
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1655.18 C-O stretching
1465.82 C-H deformation
944.64 C-H deformation
1904.34 C-O-C stretching
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Figure No.8, FTIR Studies for Isosorbide mononitrate and Poly vinyl alcohol
Wave number cm-1 Characteristic band
3221.87 C-H alkyne
2914.82 C-H stretching
1458.88 -NO2
1904.34 C-O-C stretching
3452.33 O-H stretching
1582.79 C=C stretching
1093.99 C-C stretching
Results shows that there is no interaction between drug and excioient
6.3  Evaluation of Fast dissolving film formulation
6.3.1 Physical appearance and surface texture of films:
These parameters were checked simply with visual infection of films and by feel or
touch. The observation suggests that the films are having smooth surface and they are elegant
enough to see.
6.3.2 Uniformity of weight
The  weight  of  prepared  films  was  determined  using  electronic  balance  and  the  average
weight of all film was given in the table no.7
The weight of  films measured with with HPMC,PVA and combination of  both PVA and
HPMC were about40.51±0.63 , 45.83±0.95  and 43.43±1.26 mg respectively.
 In all the cases the calculated standard deviation values are very low which suggest that the
prepared films were uniform in weight.
6.3.3 Thickness: 
Thickness of the film was another parameter. Thickness of the all formulated film was
given in the table no.7
ULTRA COLLEGE OF PHARMACY Page 61
RESULTS AND DISCUSSION
The thickness of films measured with HPMC, PVA and combination of both PVA and
HPMC were about 51.2±7.50, 68±3.012 and 67.5±10.68mm respectively. 
In all the cases the calculated standard deviation values are very low which suggest that, the
prepared films were uniform in thickness
6.3.4  Folding endurance:
Folding  endurance  is  the  index  of  ease  of  handling  the  film  which  reveals  good  film
properties. All films exhibited folding endurance above proving the flexible nature of the
film. Folding endurance of formulated film was given in the table no.7
The folding endurance of films prepared with HPMC, PVA and combination of both PVA and
HPMC were about 237.3±4.9326.6±7.6 and 256±8.02 respectively. 
6.3.5 Tensile strength
The tensile strength of all the formulation was carried out by texture analyzer. The result was 
shown in table no.7. Film with PVA showed higher tensile strength than other two 
formulations.
6.3.6 Percentage elongation 
Percentage elongation was calculated by measuring the increase in length of the film after 
tensile strength measurement by using the following formula.
Percentage Elongation = [L-L0] / L0
Where, L was the Final length, L0 was initial length. The result was shown in table no.7
The results indicate that films PVA shown higher elongation (160%) time than other two 
formulations.
6.3.7 Surface pH
Surface pH was determined by the films were allowed in contact with 1ml of distilled
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water. The surface pH of the films prepared  with HPMC ,PVA and combination of both
HPMC and PVA were about 6.67 + 0.154, 6.89 + 0.122 and 6.65 + 0.111 respectively.
Considering the fact that acidic or alkaline pH may cause irritation to the oral mucosa
and influence  the  degree  of  hydration  of  polymer,  the  surface  pH of  the  fast  films  was
determined to optimize drug permeation. Attempts were made to keep the surface pH as close
to salivary pH as possible, by the proper selection of the polymer for developing the fast
films. The surface pH of all the films was within the range of salivary pH. No significant
difference was found in surface pH of different films.
The standard deviation values calculated for all the films are very low which conclude that
the surface pH of all the films was uniform and within the ranges .The result was shown in
table no.7
6.3.8 Drug content and content uniformity
Isosorbide mononitrate films prepared with various polymers were analyzed for drug
content and content uniformity. The average drug content and content uniformity results were
shown in Table no.7. The drug content was in the range of 99.8 to 100.6%. The drug content
and content uniformity were found within pharmacopeial limit. Both the result suggesting
that drug was uniformly dispersed throughout all films.
6.3.9 In-vitro Dispersion Time 
 In-vitro dispersion time of formulated film was given in the table no.7
The In-vitro dispersion time of the films prepared with HPMC, PVA and combination films 
were about 6.3±1.53, 24.6±1.53 and16.7±2.52 respectively.
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Formulatio
n code      
Weight
( mg)
(n=10)
Thickness
     (µm)
     (n=10)
Folding
endurance
(n=10)
  
Surface pH
     (n=10)
Drug
content
(mg)%
Content 
Uniformity
(n=10)
Tensile
strength
Kg/cm2
(n=4)
       
Percentage
Elongation
(n=4)
Invitro
Dispersion
Time in sec
(n=4)
Batch-1 40.51±0.43 51.2±2.50 237.3±4.9 6.67±0.154 99.8±1.10 98.9±1.2 0.25±0.39 4.3±23.79 6.3±1.53
Batch-2 45.83±0.35 68±2.012 326.6±2.6 6.89 + 0.122 100.6±1.23 99.3±2.5 0.58±0.72 160±53.31 24.6±1.53
Batch-3 43.43±1.16 67.5±4.68 256±2.02 6.65 + 0.111 99.6±1.25 99.0±1.58 0.25±0.40 3.8±60.19 16.7±2.52
                                                          Table No: 7, Physicochemical Evaluations of Oral Thin Films
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6.3.10 In vitro Dissolution Study
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        Figure No .8, Comparative Dissolution Profiles of B 1, B 2, B3.
Table No : 8, Dissolution Study in Distilled water
Time
( min)
Cumulative percentage of drug release
B1 B2 B3
2 79.2 57.1 60.6
5 86.4 65.7 70.9
10 91.5 74.4 76.6
15 94.9 81.3 84.2
20 98.5 88.5 91.7
30 99.2 94.5 95.6
RESULTS AND DISCUSSION
The dissolution results indicate that rate and extent of films formulated with HPMC was
better than other 2 formulations. Hence film formulated with HPMC was selected as a
final formula.
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 7. SUMMARY AND CONCLUSION
Summary
 Formulation and Evaluation of fast dissolving oral film of Isosorbide mononitrate of initiated
with determination of λmax using UV spectroscopy and it  was found that λmax & it obeys
Beer’s Lamberts law. The  FTIR  characterization  of  Isosorbide  mononitrate  and  the  physical
mixture of drug and polymer indicate the absence of interaction between them. 
Initial placebo trials of polymers were taken to optimize the concentration of polymer and
composition.  Fast  dissolving oral  thin films with  selected  polymer  concentration,  films with
HPMC, PVA and  combination of  both PVA and  HPMC were formulated by solvent  casting
method. Sucralose and pineapple flavour were used to improve the palatability of films.
All the formulation were evaluated for the uniformity of weight, thickness of film, drug
content, content uniformity, tensile strength, percentage elongation, folding endurance, surface
pH, Invitro dispersion time and Invitro dissolution studies. 
The weight of films with HPMC, PVA and combination of both PVA and HPMC were 
about 40.51±0.63, 45.83±0.95 and 43.43±1.26 mg respectively. In all the films the calculated 
standard deviation values are very low which suggest that, the prepared films were uniform in 
thickness. All films exhibited folding endurance above proving the flexible nature of the film. 
The oral thin films of Isosorbide mononitrate prepared with HPMC, PVA and combination films 
prepared by solvent casting method possesses good mechanical properties. Results of texture 
analysis proved that films with PVA showed higher tensile strength than other two formulations. 
The standard deviation values of surface pH indicate that all the films all the films were uniform 
and as close to salivary pH. The drug content and content uniformity results suggesting that drug 
was uniformly dispersed throughout all films. 
The Invitro dispersion time of all the films were within 30 sec .The dissolution results
indicate  that  rate  and  extent  of  films  formulated  with  HPMC  was  greater  than  other  two
formulations. Hence film formulated with HPMC was selected as a final formula. 
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Conclusions
Film dosage form typically the size of a postage stamp that dissolves or disintegrates
quickly  in  the  oral  cavity  resulting  in  solution  or  suspension  without  the  need  for  the
administration of water is known as an oral fast dispersing dosage form. 
 There is an unmet need in the art  for an oral dosage form which includes Isosorbide
mononitrate  which  can  be  administered  conveniently  without  requiring  water  for  ingestion,
which can disintegrate rapidly, and which has a decrease potential for a patients to expel the
dosage  form after  administration and placement  of  the  dosage  form in  the  oral  cavity.  This
dosage form is convenient for the geriatric patients and bedridden patients are unwilling to take
solid do solid dosage form.
 Isosorbide mononitrate is not available as patient compliance orally disintegrating dosage
form. Thus present attempt of developing Isosorbide mononitrate oral thin film was successful
and the developed Isosorbide mononitrate oral thin film is a viable alternative for Isosorbide
mononitrate immediate release tablets.
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